Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$11.43 0.06 (0.53%)
2/9/2010 4:00 PM

Alkermes, Inc. (ALKS)

CAPS Rating:
****

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ALKS

Add Stock to Watchlist

What the Community Thinks

Total Members

210 Outperforms
8 Underperforms
 

All-Stars

76 Outperforms
2 Underperforms
 

Wall Street

3 Outperforms
1 Underperforms
 

Members bullish on ALKS are also bullish on:

Members bearish on ALKS are also bearish on:

Ticker Tags

Healthcare (711), Small Cap (1645), Options Backdating (?) (95), Biotechnology (220), Aggressive Growth (860), Defensive (1457), Growth (1902)
Suggest a tag

Alkermes, Inc. At A Glance

Current Price: $11.43
Last Trade Time: 2/9/2010 4:00 PM
Open: $0.00
Previous Close: $11.37
Daily Range: $11.40 - $11.68
52-Week Range: $7.41 - $13.16
Volume: 1,086,280
Market Cap: $1.08B
P/E Ratio: 13.20
Compare Our Special Broker Offers!

Stock Trends

ALKS VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for ALKS

More Headlines...

Top Bull Pitch

Recs

1

Alkermes, Inc. (ALKS)

Avatar lovinoptions (79.68) Submitted: 7/24/09 1:34 PM

Very high profit margin





Very low P/E





Very high forward P/E





Earnings expected to grow at a rate of 42% over the next 5 years.





Very little debt (LT Debt/Equity is .12)





I put thi...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 38 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

0

 (ALKS)

Avatar Roto1177 (77.85) Submitted: 11/14/09 2:42 PM : Outperform Start Price: $8.34 ALKS Score: 39.91

CAPS ALL STAR

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALKS)

Avatar biofest (< 20) Submitted: 11/10/09 1:06 AM : Outperform Start Price: $7.59 ALKS Score: 52.50

Great CEO. Richard Pops.Back in the job from chairman. First spoke with him ten years ago when he was 37 - very impressive.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALKS)

Avatar zzlangerhans (99.64) Submitted: 11/09/09 1:55 PM : Outperform Start Price: $7.64 ALKS Score: 51.13

Alkermes is an up-and-down kind of stock that is constantly bucked and tossed between opposing waves of optimism and pessimism. My trigger finger has been itching since it dropped below 8 and today I bought 2000 shares at 7.73. Why does Alkermes deserve a buy over other biotechs on my watchlist that appear underpriced (Allos, GTX, Neurocrine)? The main reason is safety of the investment. The five year low on the stock was 6.37, seen in November 2008, and the share price was back over 10 two weeks after that. This year the price has been as high as 13. I can't imagine this stock making a new five year low in this market, with the stable income from Risperdal Consta limiting their losses and an impending massive PDUFA for weekly exenatide in March 2010. The current weakness seems to be a shortsighted response to a minor earnings shortfall in the midst of a declining trend. Sure, the trend could carry the stub below 7 in the short-term, but if Alkermes is below 15 prior to the PDUFA I'll be surprised.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (ALKS)

Avatar curlykoa (55.41) Submitted: 11/09/09 1:29 PM : Outperform Start Price: $7.68 ALKS Score: 50.49

Financials improving around the world.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALKS)

Avatar NewlyMinted4Star (< 20) Submitted: 10/21/09 9:47 AM : Outperform Start Price: $8.95 ALKS Score: 30.11

This account tracks the performance of newly minted 4 star stocks - 3 star stocks that recently turned in to 4 star stocks.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 38 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 4 of 4  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackLeerinkSwan 92.83 11/17/09 Outperform NS $8.60+32.91%-3.34%+36.24
TrackBofASec 94.61 12/18/07 Outperform NS $14.59-21.66%-22.99%+1.33
TrackJPMorgan 84.76 11/09/07 Outperform NS $13.49-15.27%-22.89%+7.62
TrackJimCramer < 20 07/31/06 Underperform 3W $17.16-33.39%-10.33%+23.06

Results 1 - 4 of 4  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 171ms